Filing Flows › Cytokinetics (CYTK) › Q3 2026 › vs Q2 2026
Cytokinetics (CYTK) Q3 2026 vs Q2 2026 (quarter over quarter)
Cytokinetics's revenue rose $18.9M (+66%) from $28.6M in Q2 2026 to $47.6M in Q3 2026. The biggest changes: Net Product Revenue +$19.2M (+76%); Collaboration Revenues −$240K (-7%).
Cytokinetics, Q3 2026: revenue $47.6M (25× year over year), operating margin -351.3%, net loss $190M, operating cash flow −$124M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Net Product Revenue | $44.5M | $25.3M | $19.2M | +76% |
| Collaboration Revenues | $3.0M | $3.3M | −$240K | -7% |
| Revenue | $47.6M | $28.6M | $18.9M | +66% |
| Net loss | $190M | $199M | −$8.7M | -4% |
| Costs & expenses | $238M | $227M | $10.2M | +5% |
| Operating costs | $215M | $208M | $6.8M | +3% |
| Interest & other, net | $23.0M | $19.6M | $3.4M | +17% |
| Research & development | $99.3M | $97.8M | $1.5M | +2% |
| SG&A | $113M | $104M | $8.7M | +8% |
| Other operating costs | $2.2M | $5.6M | −$3.4M | -60% |
| Operating cash sources | $190M | $199M | −$8.7M | -4% |
| Depreciation & amortization | $3.6M | $3.6M | $17K | +0.5% |
| Share-based compensation | $34.7M | $35.7M | −$990K | -3% |
| Working capital & other | $27.7M | −$420K | $28.1M | — |
| Cash used in operations | $124M | $160M | −$35.8M | -22% |
| Net loss absorbed | $190M | $199M | −$8.7M | -4% |
Questions
How much did Cytokinetics's revenue grow quarter over quarter in Q3 2026?
Cytokinetics's revenue rose $18.9M (+66%) from $28.6M in Q2 2026 to $47.6M in Q3 2026.
What drove Cytokinetics's revenue change in Q3 2026?
Net Product Revenue +$19.2M (+76%); Collaboration Revenues −$240K (-7%).